RyCarma Therapeutics

Executive Summary

RyCarma Therapeutics is a private biotech company founded in 2020 and headquartered in San Diego, CA. The company is pioneering the development of small-molecule drugs targeting ryanodine receptors (RyRs), a class of ion channels that govern intracellular calcium flux in virtually all cell types and are critical for muscle contraction. By leveraging decades of foundational research, RyCarma aims to unlock the therapeutic potential of these previously undruggable targets for diseases involving calcium dysregulation, such as heart failure, arrhythmias, and skeletal muscle disorders. The company's platform could address significant unmet needs in cardiology and neuromuscular indications where current therapies are limited.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data Release70% success
• Q1 2027Series A Financing or Strategic Partnership60% success
• Q3 2027IND-Enabling Studies Initiation50% success